JUN 27, 2022 3:00 AM PDT

A Genomic Scan Detects Cancer-Driving Mutations

WRITTEN BY: Katie Kokolus

Cancer develops when the DNA in our cells becomes altered, resulting in a gene mutation.  DNA alterations can occur naturally when a cell is dividing, and usually, our body elicits mechanisms of DNA repair to fix the damage.  However, when DNA repair is not successful, a mutation can occur.  Environmental exposures such as radiation or cigarette smoke can also cause mutations.  While some mutations have no impact, others undergo uncontrolled replication, leading to cancer.

Passenger mutations, which do not elicit excessive cellular replication, make up the majority of the cancerous mutations.  Driver mutations, characterized by the ability to “drive” tumor growth, only constitute a small portion of the mutational landscape.  Driver mutations elicit various mechanisms to drive tumors, including stimulating cell growth, preventing cell death, or promoting tissue invasion. 

The genome of a tumor is often heterogeneous, meaning there is a high degree of variability from cell to cell.  This complexity makes it challenging to distinguish driver versus passenger mutations.  Identifying which mutations drive tumors can provide invaluable information.  For example, understanding specific driver mutations present in a patient can help doctors optimize treatment regimens.  Additionally, characterizing driver mutations that commonly appear will significantly advance drug development by pinpointing new targets for cancer treatment. 

To address the challenging heterogeneity of the tumor genome, a group of researchers at the Massachusetts Institute of Technology has developed a computer program to survey the tumor genome and isolate mutations that occur at a high rate.  The research team recently published a detailed explanation of the computer model, called Dig, in Nature Biotechnology

The researchers mapped the mutational rates for 37 different cancer types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) dataset.  This detailed map produced an accurate model of the expected number of passenger mutations in the genome.  Detailing the passenger mutations allowed the researchers to identify regions with a higher-than-expected accumulation of mutations, suggesting the likely presence of driver mutations among the anticipated passengers. 

Using Dig, the researchers report that driver mutations, while present at low frequency in individual cases, collectively contribute to driving cancer progression in up to 10% of tumors that carry higher-than-expected mutational loads.  The authors conclude that Dig can improve the usability of a growing body of cancer genome data.   

For more information on the cancer genome, see previous Labroots’ articles on Whole Genome Sequencing (WGS), The Cancer Genome Atlas (TCGA), and the PanCancer Atlas.

 

Sources: Science (Vogelstein), Science (Martincorena), Nature, Cell (Hanahan), Nat Biotech, Cell (Hutter)

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
MAR 10, 2022
Drug Discovery & Development
Drug Equipped with Iron Sensor Halts Cancer Tumor Growth
MAR 10, 2022
Drug Equipped with Iron Sensor Halts Cancer Tumor Growth
A modified version of an FDA-approved drug can halt tumor growth driven by mutations in the RAS gene, which are notoriou ...
APR 28, 2022
Drug Discovery & Development
Keto Molecule Shows Promise for Treating Colorectal Cancer
APR 28, 2022
Keto Molecule Shows Promise for Treating Colorectal Cancer
A molecule produced when on low-carbohydrate ketogenic diets suppresses the growth of colorectal tumors in the lab. The ...
JUN 20, 2022
Cancer
Uterine Cancer Mortality is on the Rise
JUN 20, 2022
Uterine Cancer Mortality is on the Rise
Uterine cancer develops when cells in the inner lining of the uterus, known as the endometrium, undergo uncontrolled and ...
JUN 20, 2022
Health & Medicine
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
JUN 20, 2022
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
The New England Journal of Medicine published results from a small study by researchers at New York’s Memorial Slo ...
JUN 26, 2022
Drug Discovery & Development
Vitamin Supplements are a 'Waste of Money' for Healthy Americans
JUN 26, 2022
Vitamin Supplements are a 'Waste of Money' for Healthy Americans
The US Preventive Services Task Force (USPSTF) recommends against using beta carotene or vitamin E supplements to preven ...
AUG 03, 2022
Cancer
Guide to Adherent Cell Culture Basics: Seeding, Expanding, and Harvesting
AUG 03, 2022
Guide to Adherent Cell Culture Basics: Seeding, Expanding, and Harvesting
Cell culturing is hard work. Because it's a highly technical process, there's a lot that can go wrong  ...
Loading Comments...